924,561 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Acquired by Legal & General Group Plc

Legal & General Group Plc acquired a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 924,561 shares of the biopharmaceutical company’s stock, valued at approximately $278,321,000.

Other hedge funds have also recently bought and sold shares of the company. Brandywine Managers LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $698,000. L2 Asset Management LLC acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at $231,000. Cibc World Market Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at $2,174,000. OMERS ADMINISTRATION Corp bought a new position in Alnylam Pharmaceuticals in the second quarter valued at about $1,360,000. Finally, Osmosis Investment Management UK Ltd acquired a new stake in Alnylam Pharmaceuticals in the second quarter worth about $1,095,000. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Stock Down 0.4%

Alnylam Pharmaceuticals stock opened at $239.00 on Thursday. The company has a 50 day moving average of $264.27 and a 200-day moving average of $294.77. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. Alnylam Pharmaceuticals, Inc. has a twelve month low of $197.81 and a twelve month high of $495.55. The stock has a market capitalization of $31.98 billion, a PE ratio of 44.42 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, topping analysts’ consensus estimates of $1.63 by $0.21. The business had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.32 billion. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The firm’s quarterly revenue was up 66.9% on a year-over-year basis. During the same period last year, the business posted ($0.51) earnings per share. On average, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.59 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have weighed in on ALNY shares. Royal Bank Of Canada dropped their price objective on Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating for the company in a report on Friday, July 31st. Needham & Company LLC reduced their price objective on shares of Alnylam Pharmaceuticals from $510.00 to $357.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Oppenheimer dropped their target price on shares of Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating for the company in a research report on Friday, July 31st. Wells Fargo & Company cut their price target on Alnylam Pharmaceuticals from $316.00 to $256.00 and set an “equal weight” rating on the stock in a research note on Friday, August 14th. Finally, Bank of America reduced their price target on Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating on the stock in a research report on Tuesday, July 14th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $386.14.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the sale, the director owned 1,582 shares of the company’s stock, valued at $473,302.76. This trade represents a 70.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.86% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.